Andrew M. Brunner

5.8k total citations
137 papers, 2.1k citations indexed

About

Andrew M. Brunner is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Andrew M. Brunner has authored 137 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Hematology, 40 papers in Oncology and 34 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Andrew M. Brunner's work include Acute Myeloid Leukemia Research (78 papers), Chronic Myeloid Leukemia Treatments (23 papers) and Acute Lymphoblastic Leukemia research (23 papers). Andrew M. Brunner is often cited by papers focused on Acute Myeloid Leukemia Research (78 papers), Chronic Myeloid Leukemia Treatments (23 papers) and Acute Lymphoblastic Leukemia research (23 papers). Andrew M. Brunner collaborates with scholars based in United States, Canada and United Kingdom. Andrew M. Brunner's co-authors include Amir T. Fathi, Philip C. Amrein, Donna Neuberg, David P. Steensma, Karen K. Ballen, Richard M. Stone, Vivek Upadhyay, Gabriela Hobbs, Rami S. Komrokji and Amer M. Zeidan and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Andrew M. Brunner

130 papers receiving 2.1k citations

Peers

Countries citing papers authored by Andrew M. Brunner

Since Specialization

Citations

This map shows the geographic impact of Andrew M. Brunner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew M. Brunner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew M. Brunner more than expected).

Fields of papers citing papers by Andrew M. Brunner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew M. Brunner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew M. Brunner. The network helps show where Andrew M. Brunner may publish in the future.

Co-authorship network of co-authors of Andrew M. Brunner

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew M. Brunner. A scholar is included among the top collaborators of Andrew M. Brunner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew M. Brunner. Andrew M. Brunner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation 2025 ·Leukemia Research ·Brandon J. Aubrey, Traci M. Blonquist, Malgorzata McMasters, Gabriela Hobbs, Steven L. McAfee, Jacalyn Rosenblatt, Philip C. Amrein, Christine Connolly, (unknown), Emma Logan, Bimalangshu R. Dey, Thomas R. Spitzer, (unknown), Yi‐Bin Chen, Karen K. Ballen, Areej El‐Jawahri, Amir T. Fathi, Andrew M. Brunner	1
2	Real-world outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia treated with IDH1 and IDH2 inhibitors in the frontline setting 2025 ·Blood ·(unknown), (unknown), Philip C. Amrein, Amir Fathi, Gabriela Hobbs, Hanno Hock, Rupa Narayan, Andrew M. Brunner, Michelle Lee	0
3	Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols 2024 ·Leukemia ·Yannis K. Valtis, Yael Flamand, Shai Shimony, Andrew E. Place, Lewis B. Silverman, Lynda M. Vrooman, Andrew M. Brunner, Stephen E. Sallan, Martha Wadleigh, Richard M. Stone, Daniel J. DeAngelo, Marlise R. Luskin	5
4	Safety and Activity of the TIM3 Inhibitor Sabatolimab in Patients with Lower-Risk Myelodysplastic Syndromes 2024 ·Blood ·Andrew M. Brunner, Yiwen Liu, Rupa Narayan, Michelle Lee, Philip C. Amrein, Hanno Hock, Gabriela Hobbs, Donna Neuberg, Timothy A. Graubert, Amir T. Fathi	1
5	Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy. 2024 ·Journal of Clinical Oncology ·Areej El‐Jawahri, (unknown), Joseph A. Greer, Vicki A. Jackson, Jillian Gustin, Alice S. Mims, Albert S. Cook, Thomas W. LeBlanc, (unknown), (unknown), Amir T. Fathi, Gabriela Hobbs, Andrew M. Brunner, Jennifer S. Temel	0
6	Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen 2024 ·Blood Cancer Journal ·Shai Shimony, (unknown), Yael Flamand, (unknown), (unknown), Yannis K. Valtis, Andrew E. Place, Lewis B. Silverman, Stephen E. Sallan, Lynda M. Vrooman, Andrew M. Brunner, Donna Neuberg, Ilene Galinsky, Jacqueline S. Garcia, Eric S. Winer, Martha Wadleigh, Richard M. Stone, Jean M. Connors, Daniel J. DeAngelo, Marlise R. Luskin	2
7	In-Hospital and readmission outcomes of patients with myeloproliferative neoplasms and atrial fibrillation: insights from the National Readmissions Database 2023 ·Journal of Thrombosis and Thrombolysis ·Orly Leiva, Joan How, Jeremy D. Grevet, Andrew M. Brunner, Gabriela Hobbs	3
8	In-Hospital and readmission outcomes of patients with myeloproliferative neoplasms and heart failure: Insights from the National Readmissions Database 2023 ·IJC Heart & Vasculature ·Orly Leiva, Jose Alvarez‐Cardona, Joan How, Andrew M. Brunner, Gabriela Hobbs	3
9	Abstract 11955: Hospital Readmission Outcomes After Myocardial Infarction Among Patients With Myeloproliferative Neoplasms 2023 ·Circulation ·Orly Leiva, (unknown), Andrew M. Brunner, Joan How, Gabriela Hobbs	1
10	Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and <i>BCR-ABL</i>-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin 2022 ·Haematologica ·Sabine Käyser, Chiara Sartor, Marlise R. Luskin, Jonathan Webster, Fabio Giglio, (unknown), Andrew M. Brunner, Matthias Fante, Christoph Lutz, Daniel Wolff, Anthony D. Ho, Mark J. Levis, Richard F. Schlenk, Cristina Papayannidis	14
11	Factors Associated with Health Care Utilization at the End of Life for Patients with Acute Myeloid Leukemia 2021 ·Journal of Palliative Medicine ·(unknown), P. Connor Johnson, (unknown), (unknown), Matthew Reynolds, (unknown), Jason A. Webb, Amir T. Fathi, Gabriela Hobbs, Andrew M. Brunner, Nina O’Connor, Selina M. Luger, Bhavana Bhatnagar, Thomas W. LeBlanc, Areej El‐Jawahri	9
12	Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study 2021 ·Blood ·Andrew M. Brunner, Yiwen Liu, Lourdes Mendez, Jacqueline S. Garcia, Philip C. Amrein, Donna Neuberg, Emma Dean, Simon A. Smith, Richard M. Stone, Amir T. Fathi, Matthew J. Walter, Timothy A. Graubert, Meagan A. Jacoby	6
13	Incident adverse events following therapy for acute promyelocytic leukemia 2018 ·Leukemia Research Reports ·(unknown), (unknown), Evan C. Chen, Mahesh Vidula, Olga Pozdnyakova, Andrew M. Brunner, Amir T. Fathi	7
14	The Impact of Antimicrobial Prophylaxis during Induction Chemotherapy for Acute Myeloid Leukemia in the Current Era 2017 ·Blood ·(unknown), Evan C. Chen, Gabriela Hobbs, Ashley Perry, Lillian Werner, Philip C. Amrein, Amir T. Fathi, Andrew M. Brunner	1
15	High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement 2017 ·Clinical Lymphoma Myeloma & Leukemia ·David Qualls, (unknown), Shuli Li, Andrew M. Brunner, Kerry Collier, Ephraim P. Hochberg, Philippe Armand, Tracy T. Batchelor, Yi‐Bin Chen, Zachariah DeFilipp	11
16	Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: A SEER database analysis 2014 ·Leukemia Research ·Andrew M. Brunner, Traci M. Blonquist, Hossein Sadrzadeh, Ashley Perry, Eyal C. Attar, Philip C. Amrein, Karen K. Ballen, Yi‐Bin Chen, Donna Neuberg, Amir T. Fathi	25
17	Presentation to Either the Pediatric Emergency Department or Primary Care Clinic for Acute Illness 2014 ·Pediatric Emergency Care ·Natalie Nokoff, Andrew M. Brunner, James G. Linakis, Siraj Amanullah	9
18	The Effects of Urban Sprawl on Daily Life: Smart Growth Implementation of Atlantic Station 2013 ·Transportation Research Board 92nd Annual MeetingTransportation Research Board ·Andrew M. Brunner	3
19	Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung 2013 ·Journal of Thoracic Oncology ·Andrew M. Brunner, Daniel B. Costa, Rebecca S. Heist, Elizabeth Garcia, Neal I. Lindeman, Lynette M. Sholl, Geoffrey R. Oxnard, Bruce E. Johnson, Peter S. Hammerman	41
20	Splenosis and sepsis: The born-again spleen provides poor protection 2011 ·Virulence ·Nathan T. Connell, Andrew M. Brunner, Christine Kerr, Fred J. Schiffman	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact